Coverage With Evidence Development and Expedited Approvals: Policy Proposals For FDA and CMS
This article was originally published in RPM Report
Based on stakeholder consultations, former FDA and CMS head Mark McClellan and former CMS official Sean Tunis present a potential upside for biopharma in broader use of Medicare coverage with evidence development. Pfizer executives participate in workshop on coordinating expedited drug approval, CED policies.
You may also be interested in...
CMS is proposing to deny coverage of Lilly’s Alzheimer’s “rule-out” diagnostic Amyvid. The decision is important for biopharma manufacturers for several reasons, both as a demonstration that the agency really will refuse to pay for FDA approved drugs—and for how CMS thinks it can actually use its authority to encourage research on effective AD therapies.
ULTRA bill will need changes to gain the support of influential patient group. Meanwhile, BIO is circulating a proposal to make changes to existing regulations.
A rarely-used tool for gathering data on medical technologies will get a fresh look as the agency solicits public comment on how to make CED a more meaningful and effective part of its coverage decision-making process.